惰性癌症和进展模式:肝病学试验设计中缺少的两个参数
Massimo Iavarone1, Jean-Charles Nault2,3,4, Giuseppe Cabibbo5
1Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico-Division of Gastroenterology and Hepatology, Milan, Italy.
该研究强调,常常被低估的惰性肝细胞癌 (HCC) 行为可能会影响临床试验 (CT) 的结果. 识别惰的HCC对于准确的CT解释和改进试验设计至关重要.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 临床试验设计 临床试验设计
- 癌症生物学 癌症生物学
背景情况:
- 沉默性肝细胞癌 (HCC) 的分析比攻击性形式少.
- 沉默性HCC的特点是进展风险低,客观反应或无临床影响的放射性进展缓慢.
- 惰性HCC患者往往保持无症状,并且不会死于与HCC相关的原因.
研究的目的:
- 为了研究惰与攻击性HCC行为对临床试验 (CT) 结果的影响.
- 假设惰性/侵略性HCC比例的失衡或基线行为错误估计会影响CT结果.
- 建议改善CT终点和HCC试验的统计分析.
主要方法:
- 在临床试验背景下对HCC行为进行文献综述和分析.
- 讨论导致HCC的惰性概况的因素.
- 提议改进的终点和统计方法来评估HCC试验.
主要成果:
- 惰性与攻击性HCC的比例可以影响CT的成功或失败.
- 惰性进展可能解释放射性进展和生存数据之间的差异.
- 当前的终点可能无法完全捕捉试验中的HCC行为细微差别.
结论:
- 建议通过考虑进展模式来改进与进展相关的终点.
- 像里程碑生存率或受限制的平均生存时间这样的替代统计工具可以更好地反映惰的HCC值.
- 建议将新型终点纳入早期CT或作为第三阶段CT的次要终点.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
相关概念视频
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
